Delivery Order SPE2DB20D1109-SPE2DB21FN00Z
- Not listed
- This federal contract award, valued at $1,195.55, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to supply a comprehensive range of pharmaceutical products...
- This federal contract award, valued at $1,185.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The contract covers the delivery of a wide range of pharmaceutical products and medical supplies,...
- This federal contract award, valued at $1,313.49, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of a variety of pharmaceutical products and medical supplies. The contract is a delivery order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of up to $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for...
- This federal contract award, valued at $1,052.29, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of pharmaceutical products and medical supplies to support military healthcare programs. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as...
- This federal contract award, valued at $1,572.37, was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of...
- This federal contract award, valued at $1,039.13, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the Amerisourcebergen Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of...
- This federal contract award, valued at $1,478.81, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 with the DLA Troop Support Medical, running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical...
- This federal contract award, valued at $1,399.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which runs through December 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical...
- This federal contract award, valued at $1,470.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,491.18, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical worth up to $999,999,999.00. The IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies,...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB21FN00ZDelivery Order
This federal contract award, valued at $1,011.78, was issued by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under the company's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company, Cencora, Inc., also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 10/30/20 |